Investing.comQwen · 实盘不做把握 3/10不做原因:风险收益比不佳
北京时间·🕒 发布 20:04:30·⟳ 抓取 20:06:18 +1m48s·⚡ 决策 09-04 20:10:43 +4m25s·53.2 天前
Modular Medical宣布与全美大型PBM签订Pivot胰岛素贴片泵合同，无财务条款披露
事件方向正面但盘前已+14%定价初始兴奋；无财务条款无法量化后续上行空间；$28M微市值、11.4%日波动率、$137万日均成交额使追高风险收益比极差；近20日已因FDA获批、5市场启动、软件增强等多重催化累涨68%，当前催化增量边际递减
📄 原文Investing.com↗ 原文
Modular Medical secures contract with national U.S. pharmacy manager
Lululemon slumps, Adobe names new CEO, NFP ahead - what’s moving markets SAN DIEGO - Modular Medical, Inc. (NASDAQ:MODD…
不做 Modular Medical（MODD.US）
盘前已+14%定价初始兴奋；无财务条款无法量化增量；$28M市值+11.4%日波动率+$137万日均成交额使追涨执行风险极高；近20日多重催化已累涨68%，当前PBM合同为商业化链条渐进步骤而非独立surprise，风险收益比不支持入场
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Modular Medical获全美大型PBM合同是真实商业化里程碑，但合同未披露PBM名称和财务条款，无法量化收入增量。盘前已+14%（42K股/$159K），初始兴奋已定价。公司市值仅$2800万、日波动率11.4%、日均成交$137万，流动性和波动结构不适合追涨。近20日已因FDA批准、市场启动等催化累涨68%，当前PBM合同是商业化链条中的又一步而非独立surprise。风险收益比不支持入场。
🔎 新鲜度:最早出现 2026-09-04 · 扩散 low · price-in 风险 high ↗
反向证据
- 做多前查反向 · 来源 stock_quote · 日期 2026-09-04 · 影响 invalidates
盘前已+14%但仅42K股/$159K成交；日均成交$137万、日波动率11.4%、市值$2800万；近20日+68%已含多重催化；追高风险收益比极差
检索:MODD pre-market reaction PBM contract liquidity volatility - 做多前查反向 · 来源 kb_search · 日期 2026-09-03 · 影响 weakens
8-K(9/3)为年度股东大会日期设定，非PBM合同；10-K显示公司2026年4月获FDA批准、尚未商业化发布、无产品收入；无法从披露中量化PBM合同收入贡献
检索:Modular Medical financial terms revenue PBM 原文 ↗
先例如何影响了这次决策
对本次决策的影响:未找到可比的微市值医疗器械PBM合同先例；该事件类型（无财务条款的PBM报销准入）在公开市场缺乏可量化先例
工具执行结果 · 成功 5 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 1,356 ms
{"result": "search_processed_events:agent query=`modd pivot insulin patch pump | modular medical pbm contract | modular medical pharmacy benefit manager`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.9/72 小时、7321 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续正常研判。"} - stock_quote 成功 stock_tools HTTP · 1,972 ms
{ - kb_search 成功 stock_tools HTTP · 4,775 ms
{ - search_case_library 成功 stock_tools HTTP · 1,714 ms
{"result": "search_case_library「MODD.US」—— 与这些标的相关的自家决策案例(本页 3 条,该标的全历史相关记录共 3 条；ENTER 只按该标的自己的腿统计):\n◆ MODD.US：相关历史决策 3 条 · 其中该标的 ENTER 0 条(0.0%) · 我们从没在这只票上 ENTER 过\n【对所查标的真 ENTER 过的:0 条 —— 相关案例里没有该标的自己的 ENTER 腿】\n【最近 3 条其它决策(多为「不做」,用来看这票最近在被什么消息刷屏)】\n• 2026-09-04 UTC 值得做 · ENTER LONG PDEX.US · 事件 - kb_fetch_document 成功 stock_tools HTTP · 1,789 ms
{
原文全文
展开原文 · 1,616 字
Lululemon slumps, Adobe names new CEO, NFP ahead - what’s moving markets
SAN DIEGO - Modular Medical, Inc. (NASDAQ:MODD) announced today that it has secured a contract with a national U.S. pharmacy benefit manager for its Pivot insulin delivery system, according to a press release statement.
The contract makes the company’s Pivot tubeless patch pump available through the national PBM. Modular Medical is a commercial-stage medical device company preparing for the commercial launch of the Pivot product.
"We believe this agreement with a national PBM, one of the largest in the country, represents an important commercialization milestone for our Pivot patch pump," said Jeb Besser, Chief Executive Officer of Modular Medical.
The press release did not disclose the name of the pharmacy benefit manager or financial terms of the contract.
The Pivot tubeless patch pump is a wearable insulin delivery platform designed to provide continuous subcutaneous insulin infusion with basal and bolus insulin delivery over a three-day wear period. The system is intended for people living with diabetes who require intensive insulin therapy.
Pharmacy benefit managers work with health plans, employers, pharmacies, and manufacturers to manage prescription drug benefits. They evaluate clinical value, negotiate reimbursement arrangements, and facilitate formulary placement.
Modular Medical is a commercial-stage medical device company focused on developing insulin delivery technologies for diabetes management.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
SAN DIEGO - Modular Medical, Inc. (NASDAQ:MODD) announced today that it has secured a contract with a national U.S. pharmacy benefit manager for its Pivot insulin delivery system, according to a press release statement.
The contract makes the company’s Pivot tubeless patch pump available through the national PBM. Modular Medical is a commercial-stage medical device company preparing for the commercial launch of the Pivot product.
"We believe this agreement with a national PBM, one of the largest in the country, represents an important commercialization milestone for our Pivot patch pump," said Jeb Besser, Chief Executive Officer of Modular Medical.
The press release did not disclose the name of the pharmacy benefit manager or financial terms of the contract.
The Pivot tubeless patch pump is a wearable insulin delivery platform designed to provide continuous subcutaneous insulin infusion with basal and bolus insulin delivery over a three-day wear period. The system is intended for people living with diabetes who require intensive insulin therapy.
Pharmacy benefit managers work with health plans, employers, pharmacies, and manufacturers to manage prescription drug benefits. They evaluate clinical value, negotiate reimbursement arrangements, and facilitate formulary placement.
Modular Medical is a commercial-stage medical device company focused on developing insulin delivery technologies for diabetes management.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。